Vidula Sukhatme

1.2k total citations
17 papers, 751 citations indexed

About

Vidula Sukhatme is a scholar working on Oncology, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Vidula Sukhatme has authored 17 papers receiving a total of 751 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Psychiatry and Mental health and 4 papers in Molecular Biology. Recurrent topics in Vidula Sukhatme's work include Cancer Immunotherapy and Biomarkers (8 papers), Cancer, Stress, Anesthesia, and Immune Response (4 papers) and Inflammatory mediators and NSAID effects (3 papers). Vidula Sukhatme is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Cancer, Stress, Anesthesia, and Immune Response (4 papers) and Inflammatory mediators and NSAID effects (3 papers). Vidula Sukhatme collaborates with scholars based in United States, Belgium and United Kingdom. Vidula Sukhatme's co-authors include Vikas P. Sukhatme, Gauthier Bouche, Pan Pantziarka, Lydie Meheus, Ciska Verbaanderd, Marco B.E. Schaaf, Patrizia Agostinis, Hannelore Maes, Praveen Vikas and Ilse Rooman and has published in prestigious journals such as Journal of Clinical Oncology, Frontiers in Immunology and Life Sciences.

In The Last Decade

Vidula Sukhatme

17 papers receiving 743 citations

Peers

Vidula Sukhatme

ONCOL

CTM

EPIDE

Theodore Lagattuta United States

David Meininger United States

Valérie Hindie France

Jiuxiang Zhu United States

Mihail Buse Romania

Ana Igea Spain

Christine Orr Canada

Emile G. Plise United States

Beste Turanlı Türkiye

Nilla Avanzi Italy

Theodore Lagattuta United States

Vidula Sukhatme

650 ×1.8

314 ×1.7

ONCOL

67 ×0.5

CTM

125 ×1.0

72 ×0.7

EPIDE

Citations per year, relative to Vidula Sukhatme Vidula Sukhatme (= 1×) peers Theodore Lagattuta

Countries citing papers authored by Vidula Sukhatme

Since Specialization

Citations

This map shows the geographic impact of Vidula Sukhatme's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vidula Sukhatme with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vidula Sukhatme more than expected).

Fields of papers citing papers by Vidula Sukhatme

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vidula Sukhatme. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vidula Sukhatme. The network helps show where Vidula Sukhatme may publish in the future.

Co-authorship network of co-authors of Vidula Sukhatme

This figure shows the co-authorship network connecting the top 25 collaborators of Vidula Sukhatme. A scholar is included among the top collaborators of Vidula Sukhatme based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vidula Sukhatme. Vidula Sukhatme is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Sebastian, Nikhil, William Stokes, Madhusmita Behera, et al.. (2024). The association of azole antifungals with overall survival in patients with non-small cell lung cancer receiving immune checkpoint inhibitors. The Oncologist. 30(2). 1 indexed citations

Sukhatme, Vidula, et al.. (2024). Readily available drugs and other interventions to potentially improve the efficacy of immune checkpoint blockade in cancer. Frontiers in Immunology. 14. 1281744–1281744. 2 indexed citations

Soares, Letícia, et al.. (2024). Using real-world data to accelerate the search for long COVID therapies. Life Sciences. 353. 122940–122940. 2 indexed citations

Sebastian, Nikhil, William Stokes, Madhusmita Behera, et al.. (2023). The Association of Improved Overall Survival with NSAIDs in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Clinical Lung Cancer. 24(3). 287–294. 13 indexed citations

Stokes, William A., Madhusmita Behera, Renjian Jiang, et al.. (2022). Impact of concomitant fibrates on immunotherapy outcomes for advanced non‐small cell lung cancer. Cancer Medicine. 12(1). 358–367. 7 indexed citations

Moghanaki, Drew, William A. Stokes, Madhusmita Behera, et al.. (2021). Association of concomitant NSAID and immunotherapy on outcomes in patients with non-small cell lung cancer: Analysis of the National Veterans Health Administration Database.. Journal of Clinical Oncology. 39(15_suppl). 9107–9107. 2 indexed citations

Stokes, William A., Madhusmita Behera, Renjian Jiang, et al.. (2021). Effect of antibiotic therapy on immunotherapy outcomes for non-small cell lung cancer: Analysis from the Veterans Health Administration Database.. Journal of Clinical Oncology. 39(15_suppl). 9017–9017. 2 indexed citations

Sebastian, Nikhil, William A. Stokes, Madhusmita Behera, et al.. (2021). Association of azole antifungals with survival in patients with non-small cell lung cancer receiving immunotherapy.. Journal of Clinical Oncology. 39(15_suppl). e18777–e18777. 1 indexed citations

Stokes, William A., Madhusmita Behera, Renjian Jiang, et al.. (2021). Association of proton pump inhibitors with survival in Veterans with non-small cell lung cancer receiving immunotherapy.. Journal of Clinical Oncology. 39(15_suppl). e18729–e18729. 6 indexed citations

10.

Sukhatme, Vidula, Suresh S. Ramalingam, Rafi Ahmed, & Vikas P. Sukhatme. (2019). Repurposing Food and Drug Administration–Approved Drugs to Promote Antitumor Immunity. The Cancer Journal. 25(2). 88–99. 6 indexed citations

11.

Pantziarka, Pan, Ciska Verbaanderd, Vidula Sukhatme, et al.. (2018). ReDO_DB: the repurposing drugs in oncology database. ecancermedicalscience. 12. 886–886. 99 indexed citations

12.

Pantziarka, Pan, Vidula Sukhatme, Sergio Crispino, et al.. (2018). Repurposing drugs in oncology (ReDO)—selective PDE5 inhibitors as. ecancermedicalscience. 12. 824–824. 37 indexed citations

13.

Verbaanderd, Ciska, Hannelore Maes, Marco B.E. Schaaf, et al.. (2017). Repurposing Drugs in Oncology (ReDO)—chloroquine and hydroxychloroquine as anti-cancer agents. ecancermedicalscience. 11. 781–781. 203 indexed citations

14.

Pantziarka, Pan, Gauthier Bouche, Lydie Meheus, et al.. (2016). ecancermedicalscience. ecancermedicalscience. 8. 442–442. 145 indexed citations

15.

Pantziarka, Pan, et al.. (2016). Repurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent. ecancermedicalscience. 10. 610–610. 96 indexed citations

16.

Pantziarka, Pan, Gauthier Bouche, Vidula Sukhatme, et al.. (2016). Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent. ecancermedicalscience. 10. 680–680. 85 indexed citations

17.

Sukhatme, Vidula, Gauthier Bouche, Lydie Meheus, Vikas P. Sukhatme, & Pan Pantziarka. (2015). Repurposing Drugs in Oncology (ReDO)—nitroglycerin as an anti-cancer agent. ecancermedicalscience. 9. 568–568. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact